Cancer Clinical Trials Information Platform in Hong Kong


  1. This serves merely as an information platform about cancer clinical trials operated by different institutions in Hong Kong. HKACS is not responsible for the contents, availability and operability of the trials listed.
  2. Respective institutions usually reserve all rights regarding the implementation and execution of their respective clinical trials.
  3. Patients usually need to satisfy a complex and stringent set of selection criteria before being selected/ included in certain clinical trials. Interested parties should contact respective institutions regarding further details of the trials


Cancer Site


*in alphabetical order (Last updated on 2/3/2018)


Nasopharyngeal Cancer

Institution Study Title  
CUHK Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) Click for Details
CUHK Multicenter Phase II Study of Nivolumab in Previously Treated Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma Click for Details
CUHK A phase II, open-label, randomized controlled study of PDR001 in patients with moderately differentiated/undifferentiated locally advanced recurrent or metastatic nasopharyngeal carcinoma who progressed on standard treatment Click for Details
CUHK A Two-Arm, Open-label, Randomized Phase II Study of Pembrolizumab (MK-3475) Monotherapy versus Standard Chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) (Keynote-122) Click for Details
HKU A Two-arm, Open-label, Randomized Phase II Study of Pembrolizumab (MK3475) Monotherapy versus Standard Chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) Click for Details
HKU A Phase II, open-label, randomized controlled study of PDR001 in patients with moderately differentiated/undifferentiated locally advanced recurrent or metastatic nasopharyngeal carcinoma who progressed on standard treatment Click for Details
PYNEH Prospective study on the use of curative local therapy and sequential chemotherapy for NPC patients with oligometastases [NPC-1201] Click for Details
QEH A phase II, open-label, randomized controlled study of PDR001 in patients with moderately differentiated/undifferentiated locally advanced recurrent or metastatic nasopharyngeal carcinoma who progressed on standard treatment Click for Details
QEH Prospective study on the use of curative local therapy and sequential chemotherapy for NPC patients with oligometastases Click for Details
*institution arranged in alphabetical order

For Enquiry, please contact the respective institute, HKACS is not responsible for the outcomes of the clinical trials.